Search

Your search keyword '"Lucas, Susana D."' showing total 11 results
Start Over Author "Lucas, Susana D." Publisher wiley
11 results on '"Lucas, Susana D."'

1. Chemoproteomik‐basierte Identifikation von 4‐Oxo‐β‐lactamen als Inhibitoren der Dipeptidylpeptidasen 8 und 9

Author

Carvalho, Luís A. R., primary, Ross, Breyan, additional, Fehr, Lorenz, additional, Bolgi, Oguz, additional, Wöhrle, Svenja, additional, Lum, Kenneth M., additional, Podlesainski, David, additional, Vieira, Andreia C., additional, Kiefersauer, Reiner, additional, Félix, Rita, additional, Rodrigues, Tiago, additional, Lucas, Susana D., additional, Groß, Olaf, additional, Geiss‐Friedlander, Ruth, additional, Cravatt, Benjamin F., additional, Huber, Robert, additional, Kaiser, Markus, additional, and Moreira, Rui, additional

Published
2022
Full Text
View/download PDF

2. Chemoproteomics‐Enabled Identification of 4‐Oxo‐β‐Lactams as Inhibitors of Dipeptidyl Peptidases 8 and 9

Author

Carvalho, Luís A. R., primary, Ross, Breyan, additional, Fehr, Lorenz, additional, Bolgi, Oguz, additional, Wöhrle, Svenja, additional, Lum, Kenneth M., additional, Podlesainski, David, additional, Vieira, Andreia C., additional, Kiefersauer, Reiner, additional, Félix, Rita, additional, Rodrigues, Tiago, additional, Lucas, Susana D., additional, Groß, Olaf, additional, Geiss‐Friedlander, Ruth, additional, Cravatt, Benjamin F., additional, Huber, Robert, additional, Kaiser, Markus, additional, and Moreira, Rui, additional

Published
2022
Full Text
View/download PDF

3. Cover Picture: Chemoproteomics‐Enabled Identification of 4‐Oxo‐β‐Lactams as Inhibitors of Dipeptidyl Peptidases 8 and 9 (Angew. Chem. Int. Ed. 47/2022)

Author

Carvalho, Luís A. R., primary, Ross, Breyan, additional, Fehr, Lorenz, additional, Bolgi, Oguz, additional, Wöhrle, Svenja, additional, Lum, Kenneth M., additional, Podlesainski, David, additional, Vieira, Andreia C., additional, Kiefersauer, Reiner, additional, Félix, Rita, additional, Rodrigues, Tiago, additional, Lucas, Susana D., additional, Groß, Olaf, additional, Geiss‐Friedlander, Ruth, additional, Cravatt, Benjamin F., additional, Huber, Robert, additional, Kaiser, Markus, additional, and Moreira, Rui, additional

Published
2022
Full Text
View/download PDF

4. Titelbild: Chemoproteomik‐basierte Identifikation von 4‐Oxo‐β‐lactamen als Inhibitoren der Dipeptidylpeptidasen 8 und 9 (Angew. Chem. 47/2022)

Author

Carvalho, Luís A. R., primary, Ross, Breyan, additional, Fehr, Lorenz, additional, Bolgi, Oguz, additional, Wöhrle, Svenja, additional, Lum, Kenneth M., additional, Podlesainski, David, additional, Vieira, Andreia C., additional, Kiefersauer, Reiner, additional, Félix, Rita, additional, Rodrigues, Tiago, additional, Lucas, Susana D., additional, Groß, Olaf, additional, Geiss‐Friedlander, Ruth, additional, Cravatt, Benjamin F., additional, Huber, Robert, additional, Kaiser, Markus, additional, and Moreira, Rui, additional

Published
2022
Full Text
View/download PDF

11. Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase.

Author

Lucas SD, Costa E, Guedes RC, and Moreira R

Subjects
Enzyme Inhibitors classification, Enzyme Inhibitors therapeutic use, Glycine analogs & derivatives, Glycine therapeutic use, Humans, Molecular Weight, Proteinase Inhibitory Proteins, Secretory classification, Serine Proteinase Inhibitors therapeutic use, Sulfonamides therapeutic use, Proteinase Inhibitory Proteins, Secretory therapeutic use, Pulmonary Disease, Chronic Obstructive drug therapy
Abstract

Chronic obstructive pulmonary disease (COPD) is a major increasing health problem and the World Health Organization (WHO) reports COPD as the fifth leading cause of death worldwide. COPD refers to a condition of inflammation and progressive weakening of the structure of the lung as well as irreversible narrowing of the airways. Current treatment is only palliative and no available drug halts the progression of the disease. Human neutrophil elastase (HNE) is a serine protease, which plays a major role in the COPD inflammatory process. The protease/anti-protease imbalance leads to an excess of extracellular HNE hydrolyzing elastin, the structural protein that confers elasticity to the lung tissue. Although HNE was identified as a therapeutic target for COPD more than 30 years ago, only Sivelestat (ONO-5046), an HNE inhibitor from Ono Pharmaceutical, has been approved for clinical use. Nevertheless, Sivelestat is only approved in Japan and its development in the USA was terminated in 2003. Other inhibitors in pre-clinical or phase I trials were discontinued for various reasons. Hence, there is an urgent need for low-molecular-weight synthetic elastase inhibitors and the present review discusses the recent advances on this field covering acylating agents, transition-state inhibitors, mechanism-based inhibitors, relevant natural products, and major patent disclosures., (© 2011 Wiley Periodicals, Inc.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results